文献速递白血病

三种新方案治疗复发性急性髓系白血病的随机试验表明治疗该难治性疾病仍面临持续挑战

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
PubMed 文献 · Am J Hematol · 2018-11-15

研究纳入90例首次复发或诱导/再诱导化疗难治的急性髓系白血病患者,随机接受卡铂-拓扑替康(CT)、阿伏西地联合阿糖胞苷和米托蒽醌(FLAM)或西罗莫司联合米托蒽醌、依托泊苷和阿糖胞苷(S-MEC)方案。主要终点完全缓解率在CT组为14%(5/35),FLAM组为28%(10/36),S-MEC组为16%(3/19)。作者认为FLAM方案缓解率令人鼓舞,应考虑进一步临床开发,但老年患者应慎用。

要点

  • FLAM组总缓解率为28%(10/36,90%CI 16%-43%),CT组14%(5/35,90%CI 7%-35%),S-MEC组16%(3/19,90%CI 4%-36%)。
  • 共9例治疗相关死亡,其中7例发生在FLAM组,4例为老年患者。
  • 作者结论:FLAM方案缓解率令人鼓舞,应考虑进一步临床开发,但老年患者应慎用。

核心结论

  • 作者认为FLAM方案缓解率令人鼓舞,应考虑进一步临床开发,但老年患者应慎用。

研究设计与样本

  • 随机II期试验,纳入90例首次复发或对诱导/再诱导化疗难治的急性髓系白血病患者,随机分配至CT、FLAM或S-MEC方案,每个臂采用Simon两阶段设计。

主要发现

  • 总缓解率CT组为14%(5/35,90%CI 7%-35%),FLAM组为28%(10/36,90%CI 16%-43%),S-MEC组为16%(3/19,90%CI 4%-36%)。
  • FLAM组中位年龄62岁,CT组和S-MEC组均为55岁。
  • 共9例治疗相关死亡,其中7例发生在FLAM组,4例为老年患者。

关键数值与推荐

  • 主要终点为完全缓解(CR)的获得。
  • CT方案:卡铂-拓扑替康,两药均连续输注5天。
  • FLAM方案:阿伏西地(原黄酮吡多)、阿糖胞苷和米托蒽醌,采用定时序贯方案。
  • S-MEC方案:西罗莫司联合米托蒽醌、依托泊苷和阿糖胞苷。

临床怎么用

  • 作者结论认为FLAM方案缓解率令人鼓舞,应考虑进一步临床开发,但老年患者应慎用。

局限性

  • 共9例治疗相关死亡,其中7例发生在FLAM组,4例为老年患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To improve the outcome of relapsed/refractory acute myeloid leukemia (AML), a randomized phase II trial of three novel regimens was conducted. Ninety patients were enrolled and were in first relapse or were refractory to induction/re-induction chemotherapy. They were randomized to the following regimens: carboplatin-topotecan (CT), each by continuous infusion for 5 days; alvocidib (formerly flavopiridol), cytarabine, and mitoxantrone (FLAM) in a timed sequential regimen; or sirolimus combined with mitoxantrone, etoposide, and cytarabine (S-MEC). The primary objective was attainment of a complete remission (CR). A Simon two-stage design was used for each of the three arms. The median age of the patients in the FLAM arm was older at 62 years compared with 55 years for the CT arm and the S-MEC arm. The overall response was 14% in the CT arm (5/35, 90% CI 7%-35%), 28% in the FLAM arm (10/36, 90% CI, 16%-43%), and 16% in the S-MEC arm (3/19, 90% CI, 4%-36%). There were nine treatment-related deaths, seven of which occurred in the FLAM arm with four of these in elderly patients. We conclude that the FLAM regimen had an encouraging response rate and should be considered for further clinical development but should be used with caution in elderly patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Litzow MR, Wang XV, Carroll MP, et al. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. Am J Hematol. 2018. PMID: 30370956. doi:10.1002/ajh.25333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。